Prospective Observational Study of De-Escalation of Empirical Antibiotics in Fiji’s National Hospital
Abstract
:1. Introduction
2. Results
3. Discussion
4. Materials and Method
4.1. Study Design
4.2. Setting
4.3. Participants
4.4. Definition of Key Variable
4.5. Data Collection and Analysis
4.6. Statistical Methods
4.7. Ethics
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- World Health Organization. Antimicrobial Resistance Global Report of Surveillance; World Health Organization: Geneva, Switzerland, 2014; pp. 1–5. [Google Scholar]
- O’Neill, J. Tackling Drug-Resistant Infections Globally. Final Report and Recommendations: The Review on Antimicrobial Resistance; AMR Review: London, UK, 2016; pp. 10–12. [Google Scholar]
- Dellit, T.H.; Owens, R.C.; McGowan, J.E., Jr.; Gerding, D.N.; Weinstein, R.A.; Burke, J.P.; Huskins, W.C.; Paterson, D.L.; Fishman, N.O.; Carpenter, C.F.; et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin. Infect. Dis. 2007, 44, 159–177. [Google Scholar] [CrossRef] [PubMed]
- Rhodes, A.; Evans, L.E.; Alhazzani, W.; Levy, M.M.; Antonelli, M.; Ferrer, R.; Kumar, A.; Sevransky, J.E.; Sprung, C.L.; Nunnally, M.E.; et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2016, 43, 304–377. [Google Scholar] [CrossRef] [PubMed]
- Fiji National Anitmicrobial Resistance Action Plan; Ministry of Health and Medical Service: Suva, Fiji, 2015.
- Antibiotic Guideline, 3rd ed.; Ministry of Health, Government of Fiji: Suva, Fiji, 2011.
- Leone, M.; Bechis, C.; Baumstarck, K.; Lefrant, J.-Y.; Albanèse, J.; Jaber, S.; Lepape, A.; Constantin, J.-M.; Papazian, L.; Bruder, N.; et al. De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: A multicenter non-blinded randomized noninferiority trial. Intensive Care Med. 2014, 40, 1399–1408. [Google Scholar] [CrossRef] [PubMed]
- Rattanaumpawan, P.; Werarak, P.; Jitmuang, A.; Kiratisin, P.; Thamlikitkul, V. Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: An open-label randomized controlled trial. BMC Infect. Dis. 2017, 17, 183. [Google Scholar] [CrossRef]
- Morel, J.; Casoetto, J.; Jospé, R.; Aubert, G.; Terrana, R.; Dumont, A.; Molliex, S.; Auboyer, C. De-escalation as part of a global strategy of empiric antibiotherapy management. A retrospective study in a medico-surgical intensive care unit. Crit. Care 2010, 14, R225. [Google Scholar] [CrossRef]
- Silva, B.N.; Andriolo, R.B.; Atallah, N.; Salomão, R. De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock. Cochrane Database Syst. Rev. 2013, 2018, CD007934. [Google Scholar] [CrossRef]
- De Bus, L.; Depuydt, P.; Steen, J.; Dhaese, S.; De Smet, K.; Tabah, A.; Akova, M.; Cotta, M.O.; De Pascale, G.; Dimopoulos, G.; et al. Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: The DIANA study. Intensive Care Med. 2020, 46, 1404–1417. [Google Scholar] [CrossRef]
- Lanckohr, C.; Bracht, H. Antimicrobial stewardship. Curr. Opin. Crit. Care 2022, 28, 551–556. [Google Scholar] [CrossRef] [PubMed]
- Deshpande, A.; Richter, S.S.; Haessler, S.; Lindenauer, P.K.; Yu, P.-C.; Zilberberg, M.D.; Imrey, P.B.; Higgins, T.; Rothberg, M.B. De-escalation of Empiric Antibiotics Following Negative Cultures in Hospitalized Patients With Pneumonia: Rates and Outcomes. Clin. Infect. Dis. 2020, 72, 1314–1322. [Google Scholar] [CrossRef] [PubMed]
- Bhakta, A.; Bhattacharyya, M.; Todi, S. De-escalation practice pattern in an Indian intensive care unit. Crit. Care 2010, 14, 63. [Google Scholar] [CrossRef]
- Garnacho-Montero, J.; Gutiérrez-Pizarraya, A.; Escoresca-Ortega, A.; Corcia-Palomo, Y.; Fernández-Delgado, E.; Herrera-Melero, I.; Ortiz-Leyba, C.; Márquez-Vácaro, J.A. De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med. 2013, 40, 32–40. [Google Scholar] [CrossRef]
- Liu, P.; Ohl, C.; Johnson, J.; Williamson, J.; Beardsley, J.; Luther, V. Frequency of empiric antibiotic de-escalation in an acute care hospital with an established Antimicrobial Stewardship Program. BMC Infect. Dis. 2016, 16, 751. [Google Scholar] [CrossRef]
- Moraes, R.B.; Guillén, J.A.V.; Zabaleta, W.J.C.; Borges, F.K. De-escalation, adequacy of antibiotic therapy and culture positivity in septic patients: An observational study. Rev. Bras. Ter. Intensiv. 2016, 28, 315–322. [Google Scholar] [CrossRef]
- Laupland, K.B.; Lyytikäinen, O.; Sgaard, M.; Kennedy, K.J.; Knudsen, J.D.; Ostergaard, C.; Galbraith, J.C.; Valiquette, L.; Jacobsson, G.; Collignon, P.; et al. The changing epidemiology of Staphylococcus aureus bloodstream infection: A multinational population-based surveillance study. Clin. Microbiol. Infect. 2013, 19, 465–471. [Google Scholar] [CrossRef]
- Jaganath, D.; Jorakate, P.; Makprasert, S.; Sangwichian, O.; Akarachotpong, T.; Thamthitiwat, S.; Khemla, S.; DeFries, T.; Baggett, H.C.; Whistler, T.; et al. Staphylococcus aureus Bacteremia Incidence and Methicillin Resistance in Rural Thailand, 2006–2014. Am. J. Trop. Med. Hyg. 2018, 99, 155–163. [Google Scholar] [CrossRef]
- Tong, S.Y.C.; Bishop, E.J.; Lilliebridge, R.A.; Cheng, A.C.; Spasova-Penkova, Z.; Holt, D.C.; Giffard, P.M.; McDonald, M.I.; Currie, B.J.; Boutlis, C.S. Community-Associated Strains of Methicillin-Resistant Staphylococcus aureus and Methicillin-Susceptible S. aureus in Indigenous Northern Australia: Epidemiology and Outcomes. J. Infect. Dis. 2009, 199, 1461–1470. [Google Scholar] [CrossRef] [PubMed]
Variable | Total: n = 474 n (%) |
---|---|
Sex | |
Male | 234 (49) |
Female | 240 (51) |
Age, years | |
0–13 | 0 (0.00) |
14–35 | 113 (23.8) |
36–55 | 161 (33.96) |
56–57 | 165 (34.81) |
>76 | 35 (7.38) |
Ethnicity | |
I-taukei * | 260 (54.85) |
Indo-Fijian ◊ | 180 (37.97) |
Other | 25 (5.27) |
Comorbid conditions | |
Diabetes | 127 (26.79) |
Hypertension | 101 (21.30) |
Autoimmune | 17 (3.58) |
Indication for Empirical Antibiotics | Total Study Population n (%) | Total cases De-Escalated by 72 h n (%) | Total Cases De-Escalated After 72 h n (%) | No De-Escalation n (%) |
---|---|---|---|---|
Clinical sepsis unknown foci | 196 (46%) | 58 (30%) | 81 (41%) | 57 (29%) |
Respiratory infection | 174 (37%) | 52 (30%) | 76 (44%) | 46 (26%) |
Genitourinary infection | 12 (3%) | 2 (25%) | 5 (42%) | 4 (33%) |
Neurological infection | 40 (8%) | 11 (28%) | 20 (50%) | 9 (22%) |
Gastrointestinal infection | 22 (5%) | 8 (36%) | 8 (36%) | 6 (28%) |
Skin and soft tissue | 30 (6%) | 5 (7%) | 12 (40%) | 13(43%) |
Total | 474 (100%) | 137 (29%) | 202 (43%) | 135 (28%) |
Antimicrobial Regimen | Clinical Sepsis Unknown Focus n (%) | Respiratory Infection n (%) | Neurological Infection n (%) | Gastrointestinal Infection n (%) | Genitourinary Infection n (%) | Skin and Soft Tissue Infection n (%) |
---|---|---|---|---|---|---|
Ceftriaxone + Cloxacillin | 103 (56) | 42 (24) | 19 (48) | 6 (17) | 6 (50) | 4 (13) |
Ceftriaxone | 26 (13) | 7 (4) | 4 (10) | 0 (0) | 0 (0) | 0 (0) |
Ceftriaxone + Cloxacillin + Acyclovir | 0 (0) | 0 (0) | 7 (18) | 0 (0) | 0 (0) | |
Cloxacillin + Penicillin G + Gentamicin | 19 (10) | 0(0) | 0 (0) | 0 (0) | 1 (8) | 4 (13) |
Penicillin G + Cloxacillin | 0 (0) | 21 (12) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Penicillin G + Doxycycline | 0 (0) | 34 (20) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Penicillin G + Gentamicin | 0 (0) | 20 (11) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Ampicillin + Gentamicin + Metronidazole | 0 (0) | 0 (0) | 0 (0) | 4 (18) | 4 (33) | 0 (0) |
Penicillin G | 0 (0) | 16 (9) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Ceftriaxone + Gentamicin | 7 (4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Ceftriaxone + Cloxacillin + Metronidazole | 0 (0) | 0 (0) | 4 (10) | 0 (0) | 0 (0) | 6 (20) |
Cloxacillin + Gentamicin + Metronidazole | 0 (0) | 0 (0) | 0 (0) | 3 (14) | 0 (0) | 0 (0) |
Cloxacillin + Gentamicin | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 9 (30) |
Others | 33 (17) | 34 (20) | 6 (15) | 13 (58) | 1 (8) | 7 (23) |
Microorganism | Total Blood Cultures: n = 424 (%) |
---|---|
Staphylococcus aureus (MSSA) | 15 (3.5) |
Escherichia coli (non-ESBL) | 9 (2.1) |
Klebsiella pneumoniae (ESBL) | 7 (1.6) |
Beta hemolytic Streptococcus | 6 (1.4) |
Salmonella Typhi | 3 (0.7) |
Acinetobacter baumannii | 3 (0.7) |
Klebsiella pneumoniae (non-ESBL) | 4 (0.9) |
Escherichia coli (ESBL) | 2 (0.5) |
Staphylococcus aureus (MRSA) | 2 (0.5) |
Pseudomonas aeruginosa | 2 (0.5) |
Enterobacter cloacae complex | 2 (0.5) |
Serratia marcescens | 1 (0.2) |
Acinetobacter lwoffii | 1 (0.2) |
Citrobacter freundii | 1 (0.2) |
Enterobacter (Klebsiella) aerogenes | 1 (0.2) |
Klebsiella oxytoca | 1 (0.2) |
Proteus mirabilis | 1 (0.2) |
Providencia stuartii | 1 (0.2) |
Streptococcus spp. | 1 (0.2) |
De-Escalation | ||||
---|---|---|---|---|
De-Escalation Within 72 h | De-Escalation After 72 h | OR (Odds Ratio) (95% CI) | p-Value | |
Positive Culture | 21 | 54 | 0.50 (0.30–0.89) | <0.016 |
Negative Culture | 116 | 148 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Young-Sharma, T.; Wati, S.; Sharma, V.; Naidu, R.; Tong, D.; Jenney, A. Prospective Observational Study of De-Escalation of Empirical Antibiotics in Fiji’s National Hospital. Antibiotics 2025, 14, 124. https://doi.org/10.3390/antibiotics14020124
Young-Sharma T, Wati S, Sharma V, Naidu R, Tong D, Jenney A. Prospective Observational Study of De-Escalation of Empirical Antibiotics in Fiji’s National Hospital. Antibiotics. 2025; 14(2):124. https://doi.org/10.3390/antibiotics14020124
Chicago/Turabian StyleYoung-Sharma, Tracey, Shitanjni Wati, Vikash Sharma, Ravi Naidu, Deborah Tong, and Adam Jenney. 2025. "Prospective Observational Study of De-Escalation of Empirical Antibiotics in Fiji’s National Hospital" Antibiotics 14, no. 2: 124. https://doi.org/10.3390/antibiotics14020124
APA StyleYoung-Sharma, T., Wati, S., Sharma, V., Naidu, R., Tong, D., & Jenney, A. (2025). Prospective Observational Study of De-Escalation of Empirical Antibiotics in Fiji’s National Hospital. Antibiotics, 14(2), 124. https://doi.org/10.3390/antibiotics14020124